T
he heart is remarkably plastic, changing its size, shape, and function in response to a wide variety of stimuli. Beyond birth, by far the greatest cardiac growth occurs by cellular hypertrophy, rather than hyperplasia. When normal cardiac size has been reached, additional changes in size can occur in response to stimuli such as hypertension, defective genes, or exercise, to name a few. Although some of this hypertrophy is adaptive, some of it is maladaptive and can ultimately result in cardiac failure, the largest health care burden in the United States. A great deal of attention has been paid to the molecular pathways of hypertrophy, and it is clear that they are complex, having many intersections. A series of observations has pointed toward calcineurin as a key mediator of cardiac hypertrophy, and two articles in this issue of PNAS have further underscored this assertion (1, 2) . Calcineurin is a serinethreonine phosphatase that is activated by Ca ϩ2 -calmodulin. Calcineurin dephosphorylates nuclear factor of activated T cells (NFAT), which then translocates to the nucleus where it acts combinatorially with other transcription factors to activate downstream targets. A report by Molkentin et al. in 1998 demonstrated that an activated calcineurin could provoke massive cardiac hypertrophy and that the immunosuppressive agents, cyclosporin A (CsA) and FK506, could block this process (3) . Further, expression of a downstream target of calcineurin, activated NFAT3, had the same effect and could be prevented by CsA and FK506 (3). These observations provoked heated arguments about the appropriateness of both calcineurin as a therapeutic target and immunosuppressants as drugs to prevent͞ treat cardiac hypertrophy.
Why Such Controversy?
Calcineurin has long been a therapeutic target during postsurgical attempts to prevent rejection of transplanted organs. The immunosuppressant drugs, CsA and FK506 (Fig. 1 ), form complexes with cyclophilin and FKBP12, respectively, which then complex with the catalytic subunit of calcineurin. This approach of testing the effect of pharmacologic inhibition of calcineurin activity might have seemed straightforward, but the seemingly conflicting results obtained from such trials (see below) have divided workers into camps, arguing about the promise and pitfalls of calcineurin inhibition to treat or prevent cardiac hypertrophy. The lure is obvious: drugs already exist and have been used for a considerable time. However, calcineurin is a ubiquitous protein, undoubtedly involved in many different pathways in multiple organ systems. CsA is known to cause nephrotoxicity, which may preclude its use as a prophylactic measure for hypertrophy (4) . It has also been shown that, at least in some cases, patients undergoing treatment with CsA develop hypertension and hypertrophy (5) . Finally, CsA and FK506 have targets that are independent of calcineurin (6, 7) . For these reasons, it has been argued that prophylactic administration of CsA or FK506 to prevent hypertrophy would be ill-advised.
Controversy has been ignited by inconsistent results in attempts to treat various induced and genetic models with these drugs (see Table 1 ). In an attempt to validate calcineurin as a potential drug target and to further understand the pathways of cardiac hypertrophy, genetic inhibition of calcineurin activity has now been achieved. In this issue of PNAS, two reports show convincingly that three different endogenous protein inhibitors of calcineurin can block several forms of cardiac hypertrophy (1, 2). Many of those skeptical about calcineurin's central role and its potential therapeutic target may now have a harder time making their arguments. Although the authors do not claim that calcineurin will play a role in all of hypertrophy, it is now more clear than ever that its role is a significant one.
The role of calcineurin in cardiac hypertrophy was initially posited on the basis of the finding that GATA4 and MEF2, cardiac-enriched transcription factors, were important in activating cardiac genes during hypertrophy and that NFAT could bind to GATA4 and to MEF2 (14, 15) . Because NFAT was a known target of calcineurin's action, the logical next step was to test the effect of activating calcineurin and NFAT in the heart. The key report that spawned most of the heated discussions and further tests of the inhibition of calcineurin was that mentioned above, in which CsA and FK506, both in clinical use to prevent organ rejection, prevented calcineurin-induced hypertrophy (3). Subsequently, reports have described the ability and inability of these drugs to prevent a variety of models of See companion articles on pages 3322 and 3328.
*E-mail: leinwand@stripe.colorado.edu. hypertrophy. Some of these are summarized in Table 1 , and the results are confusing. For example, inconsistent results have been achieved in ostensibly similar models of pressure overload-induced hypertrophy in which one of three outcomes was observed: hypertrophy was completely prevented, was unaffected, or it was attenuated, and the animals died as a result of CsA treatment.
The effect of calcineurin inhibition by CsA on genetic models has been tested and, whereas the hypertrophy resulting from mutations in some sarcomeric proteins can be prevented by CsA, it does not prevent the hypertrophy resulting from cardiac expression of an activated retinoic acid receptor (9) . The end result of these reports has been to leave the community of scientists who are interested in therapeutics with an unsatisfying notion about the potential for inhibition of calcineurin and cardiac hypertrophy. (1, 2) , genetic approaches were taken to inhibit calcineurin activity, but each study has unique aspects as well. Both used transgenic overexpression of protein inhibitors of calcineurin, and the use of the ␣-cardiac myosin heavy chain promoter provided cardiac-specific expression of the transgene. The inhibitors used were either truncated forms of AKAP79 and cabin-1͞cain (2) or MCIP1 (1) . The three inhibitors were tested for their effect on several distinct models of cardiac hypertrophy. The first was the well known hypertrophic response of the heart to ␤-adrenergic stimulation, and the three protein inhibitors were found to be effective in inhibiting hypertrophy. Although wild-type animals showed Ϸ22% increase in heart͞body weight in response to isoproterenol, MCIP1 expression limited hypertrophic growth to an Ϸ8% increase. Cabin-1͞cain expression reduced hypertrophic growth from a 20% increase to Ϸ10%. The effect of cabin-1͞cain activity expression was also tested on aortic constriction of the expressing transgenic mice and also used in an acute administration of the protein inhibitors via adenovirus mediated gene transfer to the rat heart, which had been subjected to aortic constriction. Both were found to be effective. An added measure of efficacy in the paper by DeWindt et al. (2) was that the authors measured calcineurin activity and showed that activity was depressed by the peptide inhibitors. However, as they note, there are reservations with the calcineurin activity assay. The authors of the MCIP1 paper tested the efficacy of MCIP1 expression on the genetic model of hypertrophy and failure resulting from cardiac expression of activated calcineurin. Once again, the effect was striking in that it was similar to the effects of treatment with CsA or FK506.
Is All Hypertrophy Bad?
Of added import was the test of the effect of MCIP1 on exercise-induced hypertrophy. Interest in this experiment stems from the little that is known about the overlap of physiologic and pathologic hypertrophic pathways. It is well appreciated that exercise conditioning results in cardiac enlargement that is beneficial, whereas hypertrophy that results from a pathologic stimulus such as pressure overload can ultimately be deleterious. MCIP1 expression was shown to be effective in inhibiting exercise-induced hypertrophy. Herein lies the rub. From a basic science perspective, it is very useful to know that the calcineurin pathway is common, at least at some level, to both forms of hypertrophy. However, these observations raise the issue of the potential deleterious effects of inhibiting hypertrophy. Both groups reported some deleterious consequences of calcineurin inhibition in their founder populations. For example, transgenic lines expressing high levels of the cabin-1͞cain or AKAP79 peptides showed thin ventricular walls, suggesting an inhibition of normal developmental hypertrophy, and mice expressing MCIP1 had a 5-10% decrease in cardiac mass (1, 2) . This potential hazard could presumably be overcome by appropriate timing and dosage. But these observations underscore the complexities of these proteins as therapeutic modalities. Consistent with these concerns are the observations in two animal models of pressure overload in which prevention of the hypertrophic response resulted in death, presumably because the initial hypertrophy is a necessary compensatory mechanism (9, 11) . In summary, the studies in this issue of PNAS show that nonpharmacologic manipulation of calcineurin activity can have profound effects on genetic, mechanical, and exercise-induced hypertrophy, as well as on normal developmental hypertrophy.
These observations solidify calcineurin's central role in cardiac hypertrophy. Whether inhibitors of its activity will be effective therapeutic agents in clinical use remains to be seen.
